1. Fujii GY, De Juan E Jr, Humayun MS, et al. Initial experience using the transconjunctival sutureless vitrectomy system for vitreoretinal surgery. Ophthalmology. 2002; 109:1814–20.
2. Byeon SH, Lew YJ, Kim M, Kwon OW. Wound leakage and hypot-ony after 25-gauge sutureless vitrectomy: factors affecting post-operative intraocular pressure. Ophthalmic Surg Lasers Imaging. 2008; 39:94–9.
Article
3. Recchia FM, Scott IU, Brown GC, et al. Small-gauge pars plana vi-trectomy: a report by the American Academy of Ophthalmology. Ophthalmology. 2010; 117:1851–7.
4. Conway BP, Campochiaro PA. Macular infarction after endoph-thalmitis treated with vitrectomy and intravitreal gentamicin. Arch ophthalmol. 1986; 104:367–71.
Article
5. Conway BP, Tabatabay CA, Campochiaro PA, et al. Gentamicin toxicity in the primate retina. Arch Ophthalmol. 1989; 107:107–12.
Article
6. Cardascia N, Boscia F, Furino C, Sborgia L. Gentamicin-induced macular infarction in transconjunctival sutureless 25-gauge vitrectomy. Int ophthalmol. 2008; 28:383–5.
Article
7. Brouzas D, Moschos MM, Koutsandrea C, et al. Gentamicin-in-duced macular toxicity in 25-gauge sutureless vitrectomy. Cutan Ocul Toxicol. 2013; 32:258–9.
Article
8. Kuo HK, Lee JJ. Macular infarction after 23-gauge transcomjunctival sutureless vitrectomy and subconjunctival gentamicin for macular pucker: a case report. Can J Ophthalmol. 2009; 44:720–1.
9. Kim JM, Ghim WH, Cho WH, et al. Ischemic retinopathy due to suspicious gentamicin retinal toxicity after primary repair of scler-al laceration. J Korean Opthalmol Soc. 2013; 54:1126–9.
Article